Latest Breaking News On - Specialty pharmacies - Page 12 : comparemela.com
URAC publishes industry-leading white paper on the future of specialty pharmacy
pressreleasepoint.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pressreleasepoint.com Daily Mail and Mail on Sunday newspapers.
Global Rare Disease Market worth US$623 73 Billion by 2031:
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Amber Specialty Pharmacy Incorporates Patient Engagement Technology to Enhance Care Coordination
Share Article
Amber Specialty Pharmacy has partnered with Houston-based MarkeTouch Media to streamline their patient communication using automated, targeted, and responsive outbound notifications across a variety of services. This addition of using patient preferred communication has allowed Amber Specialty Pharmacy to provide more focus on their patients and spend less time managing routine tasks that were consuming valuable staff resources.
Amber Specialty Pharmacy has always taken a strategic approach leveraging technology to allow us to better serve our patients. With MarkeTouch Media’s TouchPoint Management solution, we saw improvements in patient adherence, patient experience, and overall satisfaction.
Global
, by Drug Type (Tafamidis (Vyndaqel), Patisiran (ONPATTRO), Inotersen (TEGSEDI), and Others), By Disease Type (Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, and Mixed) and Wild Type), and by Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is expected to be valued at US$
35.8 million in 2018 and is estimated to exhibit a CAGR of
55.4% over the forecast period (2018-2026),
as highlighted in a new report published by Coherent Market Insights.
The increasing launches and regulatory approval of novel therapies indicated for the treatment of transthyretin amyloidosis are expected to drive growth of the market over the forecast period. For instance, in October 2018, Alnylam Pharmaceuticals, Inc. launched ONPATTRO (patisiran) in Germany. The drug is indicated for the treatment of hereditary transt
vimarsana © 2020. All Rights Reserved.